Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Melanoma 4Neoplasms 3Multiple Myeloma 3Skin Neoplasms 2Polycystic Ovary Syndrome 2Venous Thromboembolism 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Resectable Pancreatic Ductal Adenocarcinoma 1Renal Insufficiency 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Obesity 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Meningioma 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Inflammation 1

Interventions

Tamoxifen 12Specimen Handling 6Anastrozole 6Chemotherapy, Adjuvant 5Radiotherapy 4Letrozole 4afimoxifene 3Mastectomy, Segmental 3Surgical Procedures, Operative 2Simvastatin 2Radiation Dose Hypofractionation 2Radiation 2Fish Oils 2Fatty Acids, Omega-3 24,17 beta-dihydroxy-4-androstene-3-one 2telapristone acetate 1sargramostim 1ruxolitinib 1polyphenon E 1palbociclib 1fezolinetant 1exemestane 1elacestrant 1darolutamide 1bazedoxifene 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abemaciclib 1Zoledronic Acid 1Testosterone 1Tea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Intraductal, Noninfiltrating × Tablets × Clear all
NCT06033092 2025-08-28

TOLERANT

European Institute of Oncology

Phase 2 Active not recruiting
200 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡